The effective therapy of cyclosporine A with drug delivery system in experimental colitis

References

• Aberra FN, Lichtenstein GR. (2005). Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther, 21, 307–319.
   PubMed Web of Science ®Google Scholar
• Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. (1998). Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis, 4, 276–279.
   PubMed Web of Science ®Google Scholar
• Bendjelloul F, Malý P, Mandys V, Jirkovská M, Prokesová L, Tucková L, Tlaskalová-Hogenová H. (2000). Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis. Clin Exp Immunol, 119, 57–63.
   PubMed Web of Science ®Google Scholar
• Bradley PP, Priebat DA, Christensen RD, Rothstein G. (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol, 78, 206–209.
   PubMed Web of Science ®Google Scholar
• Edwards FC, Truelove SC. (1963). The course and prognosis of ulcerative colitis. Gut, 4, 299–315.
   PubMed Web of Science ®Google Scholar
• Egesten A, Eliasson M, Olin AI, Erjefält JS, Bjartell A, Sangfelt P, Carlson M. (2007). The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis, 22, 1421–1427.
   PubMed Web of Science ®Google Scholar
• Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. (1995). Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol, 10, 387–395.
   PubMed Web of Science ®Google Scholar
• Haneda S, Fukushima K, Funayama Y, Shibata C, Takahashi K, Tabata Y, Sasaki I. (2007). A new drug delivery system targeting ileal epithelial cells induced electrogenic sodium absorption: possible promotion of intestinal adaptation. J Gastrointest Surg, 11, 568–577.
   PubMed Web of Science ®Google Scholar
• Hirotani T, Lee PY, Kuwata H, Yamamoto M, Matsumoto M, Kawase I, Akira S, Takeda K. (2005). The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol, 174, 3650–3657.
   PubMed Web of Science ®Google Scholar
• Jennings C, Kusler B, Jones PP. (2009). Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immun, 15, 109–120.
   PubMed Web of Science ®Google Scholar
• Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Kitazume MT, Takayama T, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T. (2009). Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability. J Immunol, 183, 1724–1731.
   PubMed Web of Science ®Google Scholar
• Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T. (2008). Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest, 118, 2269–2280.
   PubMed Web of Science ®Google Scholar
• Kim Y, Moon JS, Lee KS, Park SY, Cheong J, Kang HS, Lee HY, Kim HD. (2004). Ca2+/calmodulin-dependent protein phosphatase calcineurin mediates the expression of iNOS through IKK and NF-kappaB activity in LPS-stimulated mouse peritoneal macrophages and RAW 264.7 cells. Biochem Biophys Res Commun, 314, 695–703.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Present DH, Lichtiger S, Hanauer S. (1997). Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol, 92, 1424–1428.
   PubMed Web of Science ®Google Scholar
• Kristensen NN, Brudzewsky D, Gad M, Claesson MH. (2006). Chemokines involved in protection from colitis by CD4+CD25+ regulatory T cells. Inflamm Bowel Dis, 12, 612–618.
   PubMed Web of Science ®Google Scholar
• Lee H, Ahn YT, Lee JH, Huh CS, Kim DH. (2009). Evaluation of anti-colitic effect of lactic acid bacteria in mice by cDNA microarray analysis. Inflammation, 32, 379–386.
   PubMed Web of Science ®Google Scholar
• Lichtiger S. (2009). Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine. Inflamm Bowel Dis, 15, 141–142.
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. (1994). Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med, 330, 1841–1845.
   PubMed Web of Science ®Google Scholar
• Mahida YR. (2000). The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis, 6, 21–33.
   PubMed Web of Science ®Google Scholar
• Mihatsch MJ, Thiel G, Ryffel B. (1988). Histopathology of cyclosporine nephrotoxicity. Transplant Proc, 20, 759–771.
   PubMed Web of Science ®Google Scholar
• Moss AC, Peppercorn MA. (2008). Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs, 68, 1157–1167.
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Matsushima Y, Kawanami C, Oshima C, Ikada Y, Chiba T. (2000). Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther, 292, 15–21.
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, Allen RD. (2004). Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation, 78, 557–565.
   PubMed Web of Science ®Google Scholar
• Navazo L, Salata H, Morales S, Dorta MC, Pérez F, de las Casas D, Avilés J. (2001). Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol, 36, 610–614.
   PubMed Web of Science ®Google Scholar
• Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98, 694–702.
   PubMed Web of Science ®Google Scholar
• Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. (1994). Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut, 35, 669–674.
   PubMed Web of Science ®Google Scholar
• Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandtzaeg P, Scott H. (1997). Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology, 112, 1493–1505.
   PubMed Web of Science ®Google Scholar
• Schenk M, Bouchon A, Seibold F, Mueller C. (2007). TREM-1–expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest, 117, 3097–3106.
   PubMed Web of Science ®Google Scholar
• Shibusawa Y, Negishi I, Tabata Y, Ishikawa O. (2008). Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly(L-lactic acid) microspheres. Rheumatology (Oxford), 47, 454–457.
   PubMed Web of Science ®Google Scholar
• Smith PD, Ochsenbauer-Jambor C, Smythies LE. (2005). Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev, 206, 149–159.
   PubMed Web of Science ®Google Scholar
• Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD. (2005). Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest, 115, 66–75.
   PubMed Web of Science ®Google Scholar
• Soriano-Izquierdo A, Gironella M, Massaguer A, Salas A, Gil F, Piqué JM, Panés J. (2004). Effect of cyclosporin A on cell adhesion molecules and leukocyte-endothelial cell interactions in experimental colitis. Inflamm Bowel Dis, 10, 789–800.
   PubMed Web of Science ®Google Scholar
• Strestíková P, Otová B, Filipec M, Masek K, Farghali H. (2001). Different mechanisms in inhibition of rat macrophage nitric oxide synthase expression by FK 506 and cyclosporin A. Immunopharmacol Immunotoxicol, 23, 67–74.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. (1988). Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res, 22, 837–858.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. (1990a). Drug delivery systems for antitumor activation of macrophages. Crit Rev Ther Drug Carrier Syst, 7, 121–148.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. (1990b). Macrophage activation for antitumour function by muramyl dipeptide-protein conjugates. J Pharm Pharmacol, 42, 13–19.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. (1990c). Phagocytosis of polymer microspheres by macrophages. Advances in Polymer Science, 94, 107–141.
   Web of Science ®Google Scholar
• Tabata Y, Inoue Y, Ikada Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14, 1677–1685.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, Kido M, Inoue S, Mikami S, Asada M, Kiriya K, Kitamura H, Ohashi S, Fukui T, Kawasaki K, Matsuura M, Ishii Y, Okazaki K, Yodoi J, Chiba T. (2006). Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology, 131, 1110–1121.
   PubMed Web of Science ®Google Scholar
• Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D’Hoore A, Penninckx F, Rutgeerts P. (2003). Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology, 125, 1025–1031.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Ikuta K, Okazaki K, Nakase H, Tabata Y, Matsuura M, Tamaki H, Kawanami C, Honjo T, Chiba T. (2003). Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig Dis Sci, 48, 408–414.
   PubMed Web of Science ®Google Scholar
• Weber A, Fein F, Koch S, Dupont-Gossart AC, Mantion G, Heyd B, Carbonnel F. (2006). Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis, 12, 1131–1135.
   PubMed Web of Science ®Google Scholar
• Williams CM, Coleman JW. (1995). Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology, 86, 244–249.
   PubMed Web of Science ®Google Scholar
• Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK. (2001). Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology, 120, 925–937.
   PubMed Web of Science ®Google Scholar
• Winer J, Jung CK, Shackel I, Williams PM. (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem, 270, 41–49.
   PubMed Web of Science ®Google Scholar
• Wolf BA, Daft MC, Koenig JW, Flye MW, Turk JW, Scott MG. (1989). Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H- or 125I-labeled ligand compared. Clin Chem, 35, 120–124.
   PubMed Web of Science ®Google Scholar